Display Settings:

Format

Send to:

Choose Destination
Ann Intern Med. 2007 Dec 18;147(12):836-9.

Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Author information

  • 1Department of Oncology, Imperial College, The Chelsea and Westminster Hospital, Barts and the London NHS Trust, and Queen Mary's University, London, United Kingdom.

Abstract

BACKGROUND:

HIV-associated multicentric Castleman disease is a rare lymphoproliferative disorder with marked systemic symptoms attributed to cytokine disarray. Many therapeutic approaches in small series of patients have proved largely unsuccessful to date.

OBJECTIVE:

To investigate the efficacy and clinicopathologic variables associated with first-line treatment for HIV-associated multicentric Castleman disease with the anti-CD20 monoclonal antibody rituximab.

DESIGN:

Single-group, open-label, phase II trial.

SETTING:

3 teaching hospitals in England.

PATIENTS:

Previously untreated patients with histologically proven HIV-associated multicentric Castleman disease.

INTERVENTION:

4 infusions of rituximab, 375 mg per m2 of body surface area, at weekly intervals.

MEASUREMENTS:

Response was evaluated clinically and radiologically and by measuring plasma Kaposi sarcoma-associated herpesvirus viral load.

RESULTS:

21 consecutive patients (18 men) with plasmablastic multicentric Castleman disease were recruited. The median follow-up was 12 months (range, 1 to 49 months). One patient died before completing therapy, 20 achieved remission of symptoms, and 14 (67%) achieved a radiologic response. The overall and disease-free survival rates at 2 years were 95% (95% CI, 86% to 100%) and 79% (CI, 49% to 100%), respectively. Plasma acute-phase proteins, immunoglobulins, and Kaposi sarcoma-associated herpesvirus viral load decreased after rituximab therapy. The main adverse effect was reactivation of Kaposi sarcoma.

LIMITATION:

The study had no comparison group.

CONCLUSION:

Rituximab may be clinically valuable as initial therapy for HIV-associated multicentric Castleman disease.

PMID:
18087054
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk